2 research outputs found
Additional file 6: Figure S5. of GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration
Representative ISHAGE-based gating strategy used for the quality control of the automatically generated cell product (CP). Debris was excluded from CD45+ cells (a). CD34+ cells were selected from viable CD45+ cells (b). Events with high expression of the CD45 marker were excluded from viable CD45+/CD34+cells (c). FSC/SSC backgate was employed to select viable CD45+/CD34+ hematopoietic progenitor cells (HPCs) with blast morphology (d). Viable CD45+/CD34+/CD133+ cells were selected (e). Events with high expression of the CD45 marker were excluded from viable CD45+/CD34+/CD133+ cells (f). FSC/SSC backgate was employed to select viable CD45+/CD34+/CD133+ HPCs with blast morphology (g). A control gate (‘Ly’, lymphocytes) was used during exclusion of mature CD45+ HSCs. Red: target cell population. Gray: dead cells. (PDF 374 kb
Additional file 3: Table S2. of GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration
Overview of data obtained from manual cell isolation. Volumes of bone marrow (BM) samples were ascertained by visual control. Total numbers of viable CD133+ cells were determined using Neubauer hemocytometer. The frequencies of viable CD133+ cells were measured by flow cytometry in accordance with ISHAGE guidelines. (DOC 36 kb